CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has successfully completed patient recruitment for its two Phase II clinical trials involving the company’s first product, Vascugel™. The Phase II clinical studies are to evaluate the continued safety of Vascugel™ as well as its efficacy in the maintenance of vascular patency after creation of arteriovenous (AV) access grafts and AV fistulae in patients undergoing dialysis for treatment of end-stage renal disease (ESRD). Recent Phase I results for Vascugel™ demonstrated that all primary endpoints of the study were achieved, with no significant safety issues.
